Oct 4, 2013

Posted by in Featured, Stock Market News | 0 Comments

Gainers and Losers of the Day: ReneSola Ltd. (ADR)(NYSE:SOL), Hanwha Solarone Co Ltd(NASDAQ:HSOL), Incyte (NASDAQ:INCY) and AstraZeneca (NYSE:AZN)

Gainers and Losers of the Day: ReneSola Ltd. (ADR)(NYSE:SOL), Hanwha Solarone Co Ltd(NASDAQ:HSOL), Incyte (NASDAQ:INCY) and AstraZeneca (NYSE:AZN)

Incyte (NASDAQ:INCY) shows Proof-of-Concept Phase II trial data for oral JAK1 inhibitor for patients with Chronic Plaque Psoriasis.

The firm declared results from a 28-day, placebo-managed, dose-escalation Phase II proof-of-concept clinical trial concerning 50 patients with chronic plaque psoriasis for its proprietary oral JAK1 inhibitor, INCB39110.

Hanwha Solarone Co Ltd(NASDAQ:HSOL) settled +4.18% higher at $4.99 on high volume of 5.08 million shares during the last trading day. The stock has its 12-month high at $5.16 and 52-week low price was $0.77.

Hanwha SolarOne Co., Ltd. (Hanwha SolarOne) is an integrated manufacturer of silicon ingots, silicon wafers, PV cells and PV modules in China.

ReneSola Ltd. (ADR)(NYSE:SOL) saw its price fall on below-normal volume, as 5.04 million shares changed hands, when compared with its average daily volume of 3.91 million shares. The stock was down -1.17% to close at $5.07.

ReneSola Ltd (ReneSola), incorporated on March 17, 2006, is a global manufacturer of solar wafers and producer of solar power products based in the People’s Republic of China.

Amgen and AstraZeneca (NYSE:AZN) will show data at the EADV (Oct 2-6) showing Phase 2 data for AMG827 met its primary and secondary end-pts . Amgen will provide update and abstracts on Oct 4. AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation.

Comments are closed.